Advitech Reports Positive Study Results
QUEBEC CITY, QuebecAdvitech Solutions presented results from an ongoing open label clinical study during the 10th International Psoriasis Symposium, held in Toronto June 10 to 13. According to Advitech, the study was designed to evaluate the safety and efficacy of its product, XP-828La mix of growth factors from whey protein, in psoriasis.
Eleven adults with chronic stable plaque psoriasis received 5 g twice daily of XP-828L for 56 days. At the end of the study, seven subjects had an improvement of their psoriasis condition, with no adverse effects reported.
The results of this study will help us in positioning the XP-828L as both a safe and effective solution for treating psoriasis, said Renaud Beauchesne, president and chief executive officer of Advitech (www.advitech.com).